MEDIPURE ANNOUNCES KEY ADDITION TO CORPORATE TEAM

Rman Walia

Vancouver, BC –May, 2019 - Medipure Holdings. Inc., parent company of Medipure Pharmaceuticals Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Rman Walia, CPA, CA as its Corporate Controller.

Mr. Walia received Canadian CPA in July, 2015, his CA from New Zealand in March, 2010 and his CA from India in April, 2001. He also holds a Bachelor’s Degree in Commerce (HONS) from Punjab University in Chandigarh, India and a Diploma in Business Management from Auckland University of Technology, Auckland, New Zealand.

Mr. Walia has extensive Canadian & International corporate experience in the oil & gas, manufacturing and retail industries.  His previous responsibilities include the financial planning and reporting for an entire Canadian operation, and for projects from start to commercialization. He also introduced stringent cost control and cost reduction measures to optimize manufacturing and R&D overhead costs, as well as being heavily involved with Kaizen projects for continuous improvement including emphasis on the application of Lean Principles.

CEO, Boris Weiss, welcomes the addition of Mr. Walia as the company continues to grow and move forward with a new manufacturing facility and lab expansion in British Columbia and internationally with its subsidiaries in India, Medipure LifeSciences India (MLSI) Pvt Ltd., and Croatia, (Medipure d.o.o.)

Medipure’s research is focused on the body’s endocannabinoid system, a previously under-explored network of receptors throughout the body that plays a role in many biological and physiological functions. It’s focused on the development of a non-addictive prescription drug line to address chronic pain, anxiety and a variety of other conditions. The drug formulations could be an economical, non-addictive alternative to opioid and benzodiazepine-based prescription drugs that can be highly addictive with life-altering side effects.